FDA Weighs New Alzheimer’s Drug—but Benefits Are Uncertain
TOO GOOD TO BE TRUE?
The agency is to decide by June 7 whether to greenlight Biogen’s drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts.
